Medically reviewed by Drugs.com. Last updated on Jan 16, 2019.
(la MI vyoo deen)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Epivir: 10 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]
Epivir HBV: 5 mg/mL (240 mL) [contains methylparaben, propylene glycol, propylparaben; strawberry-banana flavor]
Generic: 10 mg/mL (240 mL)
Epivir: 150 mg [scored]
Epivir: 300 mg
Epivir HBV: 100 mg
Generic: 100 mg, 150 mg, 300 mg
Brand Names: U.S.
- Epivir HBV
- Antihepadnaviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HBV)
- Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)
Lamivudine is a cytosine analog. In vitro, lamivudine is triphosphorylated, the principle mode of action is inhibition of HIV reverse transcription via viral DNA chain termination; inhibits RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase. In hepatitis B, the monophosphate form of lamivudine is incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination.
Into extravascular spaces
Children (n=38): CSF concentrations were 14.2 ± 7.9% of the serum concentration
Vd: 1.3 ± 0.4 L/kg
Minor; only known metabolite is trans-sulfoxide metabolite
Primarily urine (majority as unchanged drug); weight-corrected oral clearance is highest at age 2 years, then declines from age 2 to 12 years, where values then remain comparable to adult values
Time to Peak
Pediatric patients 0.5 to 17 years: Median: 1.5 hours (range: 0.5 to 4 hours) (Lewis 1996)
Adolescents 13 to 17 years: 0.5 to 1 hour
Adults: Fed: 3.2 hours; Fasted: 0.9 hours
Intracellular: 10 to 15 hours
Children 4 months to 14 years: 2 ± 0.6 hours
Adults: 5 to 7 hours; increased with renal impairment
Special Populations: Renal Function Impairment
AUC and Cmax are increased.
Use: Labeled Indications
Chronic hepatitis B (Epivir HBV): Treatment of chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation
Limitations of use: Use only when an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine-HBV has not been evaluated in patients coinfected with HIV, hepatitis C virus, or hepatitis delta virus; with decompensated liver disease; or in liver transplant recipients.
HIV-1 infection, treatment (Epivir): Treatment of HIV-1 in combination with other antiretroviral agents
Off Label Uses
HIV-1 nonoccupational postexposure prophylaxis
Based on the Centers for Disease Control and Prevention, US Department of Health and Human Services updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV, lamivudine (in conjunction with other antiretrovirals) is an effective and recommended treatment option for postexposure prophylaxis of HIV-1 infection following nonoccupational exposure (nPEP) in individuals exposed to blood, genital secretions, or other potentially infectious body fluids that may contain HIV when that exposure represents a substantial risk for HIV transmission.
Prevention of perinatal HIV transmission
Based on the Health and Human Services (HHS) Perinatal HIV Guidelines, lamivudine, in combination with zidovudine and nevirapine, is a recommended regimen for empiric therapy to reduce the risk of perinatal transmission of HIV in HIV-exposed infants at higher risk of HIV-acquisition, including those born to HIV-infected women who did not receive antepartum or intrapartum antiretroviral drugs (ARV), who received only intrapartum ARV drugs, or who received antepartum and intrapartum ARV drugs but had a detectable viral load near delivery (particularly if delivery was vaginal), or mothers with acute HIV infection during pregnancy or breastfeeding. Empiric therapy with this combination provides prophylaxis against HIV acquisition and provides early treatment if HIV infection is later confirmed.
Hypersensitivity to lamivudine or any component of the formulation
Note: The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV; tenofovir and lamivudine are a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone in a fully suppressive antiretroviral regimen and for the treatment of HBV coinfection (HHS [adult] 2017).
HIV-1 infection, treatment (Epivir, 3TC [Canadian product]): Oral (use in combination with other antiretroviral agents): 150 mg twice daily or 300 mg once daily
Note: Lamivudine is a component of recommended initial regimens for any ART-naive patient (when coadministered with tenofovir plus dolutegravir or with tenofovir plus raltegravir) or for ART-naive patients who are HLA-B*5701 negative (when coadministered with abacavir plus dolutegravir) (HHS [adult] 2017).
HIV-1 nonoccupational postexposure prophylaxis (nPEP) (Epivir) (off-label use) (HHS [nPEP] 2016): Oral: Note: Initiate therapy within 72 hours of exposure and continue for 28 days; use in combination with other antiretroviral agents.
CrCl ≥60 mL/minute: Lamivudine is not a component of the recommended antiretroviral regimens for these patients.
CrCl <60 mL/minute: Dose should be adjusted based on renal function.
Treatment of hepatitis B (Epivir HBV, Heptovir [Canadian product]): Oral: 100 mg once daily
Treatment duration (AASLD practice guidelines): Treatment duration for nucleos(t)ide analog-based therapy (eg, lamivudine) is variable and influenced by HBeAg status, duration of HBV suppression, and presence of cirrhosis/decompensation (AASLD [Terrault 2016):
Patients without cirrhosis:
Hepatitis B e antigen (HBeAg) positive immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged duration of therapy is often required in patients treated with nucleos(t)ide analogues. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion
HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients.
Patients with cirrhosis:
HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation.
HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data).
Viral breakthrough (AASLD practice guidelines): Patients with confirmed viral breakthrough (HBV DNA ≥100 units/mL with previously undetectable levels [<10 units/mL] or >1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance or receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (AASLD [Terrault 2016]).
Treatment of hepatitis B/HIV coinfection (in patients with both infections requiring treatment) (Epivir): Note: The formulation and dosage of Epivir HBV are not appropriate for patients infected with both HBV and HIV. Tenofovir and lamivudine are a preferred NRTI backbone in a fully suppressive antiretroviral regimen for the treatment of HIV/HBV coinfection (HHS [adult] 2017).
Oral: 150 mg twice daily or 300 mg once daily, in combination with other antiretrovirals in an antiretroviral (ARV) regimen (HHS [adult] 2017)
Refer to adult dosing.
Note: Oral solution is available in two concentrations (10 mg/mL [eg, Epivir] and 5 mg/mL [Epivir-HBV]); use extra precaution during calculations to ensure accurate mg of lamivudine administered (HHS [pediatric 2018]). Gene mutation and ARV resistance patterns should be evaluated (refer www.IASUSA.org for more information) when necessary.
HIV-1 infection, treatment: Use in combination with other antiretroviral agents: Oral:
Infants <3 months: Limited data available: Oral solution: 4 mg/kg/dose twice daily (HHS [pediatric 2018]; HHS [perinatal 2017]; Tremoulet 2007)
Infants ≥3 months to Children <3 years: Oral solution: 5 mg/kg/dose twice daily; maximum dose: 150 mg/dose (HHS [pediatric 2018])
Children ≥3 years and Adolescents: Note: Scored tablet is preferred formulation in patients weighing ≥14 kg who are able to swallow a solid oral dosage form.
Oral solution: 5 mg/kg/dose twice daily; maximum dose: 150 mg/dose
Oral tablet: Weight-band dosing for patients weighing ≥14 kg who are able to swallow tablets (using scored 150 mg tablets):
14 to <20 kg: 75 mg (1/2 tablet) twice daily
20 to <25 kg: 75 mg (1/2 tablet) in the morning and 150 mg (1 tablet) in the evening
≥25 kg: 150 mg (1 tablet) twice daily
Once-daily dosing: Note: Not recommended as initial therapy in children. Patients can be transitioned to once daily treatment with the oral solution or tablet after stable on twice-daily treatment for ≥36 weeks with an undetectable viral load and stable CD4 count (HHS [pediatric 2018]).
Oral solution: 10 mg/kg/dose once daily; maximum dose: 300 mg/dose
Oral tablet: Weight-band dosing for patients ≥14 kg who are able to swallow tablets (scored 150 mg tablets):
14 to <20 kg: 150 mg (1 tablet) once daily
20 to <25 kg: 225 mg (1 + 1/2 tablet) once daily
≥25 kg: 300 mg (2 tablets) once daily
HIV-1 nonoccupational postexposure prophylaxis (nPEP): Note: Initiate therapy within 72 hours of exposure and continue for 28 days in combination with other retroviral agents (HHS [nPEP] 2016): Oral:
Infants, Children, and Adolescents <16 years:
Weight-directed dosing: Oral solution: 4 mg/kg (maximum dose: 150 mg/dose) twice daily has been recommended (HHS [nPEP 2016]); however, based on newer pharmacokinetic data, a higher dose of 5 mg/kg/dose twice daily has been recommended for HIV treatment in patients ≥3 months of age (HHS [pediatric 2018])
Weight-band dosing: Oral tablet: For patients ≥14 kg who are able to swallow tablets (scored 150 mg tablets):
14 to <20 kg: 75 mg (1/2 tablet) twice daily
20 to <25 kg: 75 mg (1/2 tablet) in the morning and 150 mg (1 tablet) in the evening
≥25 kg: 150 mg (1 tablet) twice daily
Adolescents ≥16 years: Oral solution or tablet:
<50 kg: 4 mg/kg twice daily; maximum dose: 150 mg/dose
≥50 kg: 150 mg twice daily or 300 mg once daily
HIV-1 perinatal transmission, prevention (HHS [perinatal 2017]): Note: A combination prophylaxis regimen is recommended for neonates at high risk of perinatal HIV transmission. If infant is diagnosed as HIV positive, convert dosing to a treatment regimen.
Three-drug combination (with nevirapine and zidovudine): Limited data available: Infants ≤6 weeks: Oral: Oral solution: 4 mg/kg/dose every 12 hours to complete up to a total duration of lamivudine therapy of 6 weeks (ie, completion of the course of therapy initiated at birth)
Hepatitis B, treatment (non-HIV-exposed/-positive): Note: Use in HBV treatment is discouraged due to rapid resistance development; consider use only if other anti-HBV antiviral regimens with more favorable resistance patterns cannot be used.
Epivir HBV: Children ≥2 years and Adolescents: Oral: 3 mg/kg/dose once daily; maximum daily dose: 100 mg/day
Heptovir [Canadian product]: Adolescents ≥16 years: Oral: 100 mg once daily
AASLD practice guidelines (Lok 2009): Treatment duration:
Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat ≥1 year until HBeAg confirmed seroconversion and undetectable serum HBV DNA; continue therapy for ≥6 months after HBeAg seroconversion
HBeAg negative chronic hepatitis: Treat >1 year until hepatitis B surface antigen (HBsAg) clearance
Note: Patients not achieving <2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok 2009)
Hepatitis B/HIV coinfection, treatment of both infections: Infants, Children, and Adolescents: Dosing should be based on recommendations for treatment of HIV infection (higher dose) not hepatitis B, as part of an appropriate cART regimen (HHS [pediatric 2018]; HHS [OI pediatric 2018]).
Oral: May be administered without regard to meals.
Some products may contain sucrose.
Epivir: Store at 25°C (77°F) tightly closed.
Epivir HBV: Store at 20°C to 25°C (68°F to 77°F) tightly closed.
Tablet: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Monitor therapy
Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. Avoid combination
Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine. Avoid combination
Orlistat: May decrease the serum concentration of Antiretroviral Agents. Monitor therapy
Sorbitol: May decrease the serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure. Consider therapy modification
Trimethoprim: May increase the serum concentration of LamiVUDine. Monitor therapy
Incidence data include patients on combination therapy with other antiretroviral agents.
Central nervous system: Headache (35%), fatigue (≤27%), malaise (≤27%), paresthesia (≤15%), peripheral neuropathy (≤15%), neuropathy (12%), insomnia (≤11%), sleep disorder (≤11%)
Dermatologic: Skin rash (9% to 12%)
Gastrointestinal: Nausea (≤33%), diarrhea (adults: 14% to 18%, children: 8%), pancreatitis (≤18%; higher percentage in pediatric patients), sore throat (13%), vomiting (≤13%)
Hematologic & oncologic: Neutropenia (7% to 15%)
Hepatic: Increased serum alanine aminotransferase (adults: 4% to 27%, children: 1%), hepatomegaly (children: 11%, adults: <1%)
Infection: infection (25%; includes ear, nose, and throat)
Neuromuscular & skeletal: Musculoskeletal pain (12%)
Respiratory: Nasal signs and symptoms (8% to 20%), cough (15% to 18%)
Miscellaneous: Fever (children: 25%, adults: ≤10%)
1% to 10%:
Central nervous system: Dizziness (10%), chills (≤10%), depression (9%)
Endocrine & metabolic: Increased amylase (2% to 4%)
Gastrointestinal: Increased serum lipase (adults: 10%, children: 3%), anorexia (≤10%), decreased appetite (≤10%), abdominal pain (9%), abdominal cramps (6%), stomatitis (children: 6%, adults: <1%), dyspepsia (5%)
Hematologic & oncologic: Lymphadenopathy (children: 9%), splenomegaly (children 5%, adults <1%), thrombocytopenia (adults: 4%, children: 1%), decreased hemoglobin (2% to 4%)
Hepatic: Increased serum aspartate aminotransferase (2% to 4%)
Neuromuscular & skeletal: Increased creatine phosphokinase (9%), myalgia (8%), arthralgia (5%)
Otic: Ear disease (children: 7%)
Respiratory: Abnormal breath sounds (children: ≤7%; adults: <1%), wheezing (children: ≤7%, adults: <1%)
<1%, postmarketing, and/or case reports: Alopecia, anaphylaxis, anemia, asthenia, cramps, exacerbation of hepatitis B, hyperbilirubinemia, hyperglycemia, immune reconstitution syndrome, lactic acidosis, liver steatosis, muscle cramps, myasthenia, pruritus, pure red cell aplasia, redistribution of body fat, rhabdomyolysis, urticaria
Concerns related to adverse effects:
• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.
• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases; suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. Use with caution in patients with risk factors for liver disease (risk may be increased with female gender or obesity) and discontinue in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).
• Pancreatitis: Has been reported, particularly in HIV-infected pediatric patients with a history of nucleoside use. Discontinue treatment if signs of symptoms of pancreatitis occur.
• Chronic hepatitis B: [US Boxed Warning]: Severe acute exacerbations of hepatitis B (some fatal) have been reported in patients with HBV or HIV/HBV coinfection who have discontinued lamivudine; hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months after discontinuation. Initiate antihepatitis B (HBV) medications if clinically appropriate.
• Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.
- HIV: [US Boxed Warning]: HIV-1 resistance may emerge in chronic hepatitis B-infection patients with unrecognized or untreated HIV-1 infection. Counseling and HIV testing should be offered to all patients before beginning treatment with lamivudine for hepatitis B and then periodically during treatment. Lamivudine dosing for hepatitis B is subtherapeutic if used for HIV-1 infection treatment. Lamivudine monotherapy is not appropriate for HIV-1 infection treatment. Lamivudine resistant HIV-1 can develop rapidly and limit treatment options if used in unrecognized or untreated HIV-1 infection or if a patient becomes coinfected during HBV treatment. Lamivudine dosing for hepatitis B is also subtherapeutic if used for HIV-1/HBV coinfection treatment. If lamivudine is chosen as part of a HIV-1 treatment regimen in coinfected patients, the higher lamivudine dosage indicated for HIV-1 therapy should be used, with other drugs, in an appropriate combination regimen.
- HBV: Patients treated with lamivudine-HBV with YMDD-mutant HBV showed diminished treatment response (lower rates of HbeAg seroconversion and HbeAg loss, more frequent return of positive HBV DNA, more frequent ALT elevations) compared to patients without evidence of YMDD substitutions. Emergence of lamivudine resistant HBV variants has also been reported in HIV-1/HBV coinfected patients who have received lamivudine-containing antiretroviral regimens.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information
• Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HCV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.
• Pediatric: Use with caution in pediatric patients with a history of prior antiretroviral nucleoside exposure or pancreatitis, or other significant risk factors for development of pancreatitis.
Dosage form specific issues:
• Appropriate product selection: Epivir HBV: [US Boxed Warning]: Do not use Epivir HBV tablets or Epivir HBV oral solution for the treatment of HIV.
• Oral solution: Use of lamivudine oral solution has been associated with lower rates of virologic suppression, lower plasma lamivudine exposure, and increased rates of resistance when compared to lamivudine tablets in pediatric clinical trials. Lamivudine scored tablet is the preferred formulation for HIV-1 infected pediatric patients weighing ≥14 kg and for whom a solid dosage form is appropriate; consider more frequent monitoring of HIV-1 viral load if oral solution is used.
• Sucrose: Lamivudine oral solutions contains 3 g of sucrose/15 mL; advise diabetic patients of sucrose content.
• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).
• Appropriate use:
-HIV: Do not use as monotherapy in treatment of HIV. Treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance; HIV-infected patients should be screened for hepatitis B prior to starting lamivudine HIV therapy. Lamivudine combined with emtricitabine is not recommended as a dual-nucleoside reverse transcriptase inhibitor (NRTI) combination due to similar resistance patterns and negligible additive antiviral activity. Do not use lamivudine/abacavir (plus efavirenz or plus atazanavir/ritonavir) in adolescent and adult HIV-1 patients with a pre-ART HIV RNA >100,000 copies/mL (HHS [adult] 2017).
- HBV: Current clinical hepatitis B practice guidelines do not recommend lamivudine for initial use in the management of chronic HBV due to low barrier to resistance; other antiviral agents with a high genetic barrier to drug resistance are preferred (eg, tenofovir or entecavir) (AASLD [Terrault 2016]).
- HIV/HBV coinfection: Lamivudine and tenofovir is a recommended NRTI backbone in a fully suppressive antiretroviral regimen to provide activity against both HIV and HBV (HHS [adult] 2017).
All patients: Hepatic function, signs/symptoms of lactic acidosis; signs/symptoms of pancreatitis
HIV patients: Coinfection with HBV (prior to therapy); HIV viral load and CD4 count; immune reconstitution syndrome
Hepatitis B patients: Coinfection with HIV (prior to therapy); following discontinuation, monitor hepatic function closely with both clinical and laboratory follow/up for signs/symptoms of HBV relapse/exacerbation (continue for at least several months after stopping treatment)
Chronic Hepatitis B: HBV DNA and ALT (HBV DNA usually done every 3 months until undetectable and then every 3 to 6 months thereafter); HBeAg; anti-HBe (in patients who are HBeAg-positive to monitor for seroconversion); HBsAg; during therapy, consider monitoring amylase (if symptoms of pancreatitis) and lactic acid levels (if clinical concern); following discontinuation, monitor for recurrent viremia, ALT flares, seroreversion, and clinical decompensation every 3 months for at least 1 year (AASLD [Terrault 2016]). As antivirals do not eliminate the risk of hepatocellular carcinoma, continued monitoring for this complication is recommended in at-risk patients.
Lamivudine has a high level of transfer across the human placenta.
No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy). An increased risk of stillbirth, low birth weight, and small for gestational age infants has been observed in some but not all studies. Based on data collected by the antiretroviral pregnancy registry, the risk of spontaneous abortions, induced abortions, and preterm birth is less in lamivudine-containing regimens compared with regimens without lamivudine. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general, NRTIs are well tolerated and the benefits of use generally outweigh potential risk.
The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine a preferred NRTI for HIV infected pregnant females who are antiretroviral-naive, who have had ART therapy in the past but are restarting, who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen), and who are not yet pregnant but are trying to conceive. In addition, females who become pregnant while taking lamivudine may continue if viral suppression is effective and the regimen is well tolerated. The pharmacokinetics of lamivudine during pregnancy are not significantly altered, and dosage adjustment is not required.
The Health and Human Services (HHS) Perinatal HIV Guidelines consider lamivudine in combination with either abacavir or tenofovir disoproxil fumarate to be a preferred NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The lamivudine/abacavir backbone is not recommended with atazanavir/ritonavir or efavirenz if pretreatment HIV RNA is >100,000 copies/mL. In addition, the HHS Perinatal HIV Guidelines consider lamivudine in combination with abacavir and dolutegravir to be a preferred INSTI regimen for initial therapy in antiretroviral-naive pregnant females who present after the first trimester (dolutegravir combinations are not recommended in pregnant females prior to 14 weeks gestation or females trying to conceive). The guidelines consider lamivudine with zidovudine to be an alternative NRTI backbone for initial therapy in antiretroviral-naive pregnant females. The guidelines also consider lamivudine plus tenofovir disoproxil fumarate a recommended dual NRTI backbone in regimens for HIV/HBV-coinfected pregnant females. Use caution with hepatitis B coinfection; hepatitis B flare may occur if lamivudine is discontinued.
In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. Monitoring during pregnancy is more frequent than in non-pregnant adults. ART should be continued postpartum for all females living with HIV and can be modified after delivery.
In hepatitis B-infected women (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines suggest antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with an HBV DNA >200,000 units/mL. There are limited data on the level of HBV DNA for when antiviral therapy is routinely recommended (>200,000 units/mL is a conservative recommendation); however, the AASLD recommends against antiviral therapy to reduce the risk of perinatal transmission in HBsAg-positive pregnant women with an HBV DNA ≤200,000 units/mL. Lamivudine is one of the antivirals that has been studied in pregnant women, with most studies initiating antiviral therapy at 28 to 32 weeks gestation and discontinuing antiviral therapy between birth to 3 months postpartum (monitor for ALT flares every 3 months for 6 months following discontinuation). There is insufficient long-term safety data in infants born to mothers who took antiviral agents during pregnancy (AASLD [Terrault 2016]).
Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2018).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience headache, nausea, diarrhea, loss of strength and energy, rhinitis, rhinorrhea, dizziness, pharyngitis, or ear irritation. Have patient report immediately to prescriber signs of lactic acidosis (fast breathing, tachycardia, abnormal heartbeat, vomiting, fatigue, shortness of breath, severe loss of strength and energy, severe dizziness, feeling cold, or muscle pain or cramps), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of pancreatitis (severe abdominal pain, severe back pain, severe nausea, or vomiting), depression, burning or numbness feeling, or signs of infection (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
- What drugs are contained in Symfi Lo?
- How much does Cimduo cost?
- What drugs are contained in Cimduo?
- What drugs are contained in Delstrigo?
More about lamivudine
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 3 Reviews
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)